Results 181 to 190 of about 99,760 (303)

Corrigendum: The Value of Liver Transplantation for Methylmalonic Acidemia

Frontiers in Pediatrics, 2020
Yi-Zhou Jiang, Yi-Zhou Jiang, Li-Ying Sun, Li-Ying Sun, Li-Ying Sun   +4 more
doaj   +1 more source

Association of GLP‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation and the risk of hepatic decompensation compared with dipeptidyl peptidase 4 inhibitors (DPP4is) in a racially and ethnically diverse cohort of adults with Type 2 diabetes.
Inyoung Hwang, Yun Kim, Sang Won Lee
wiley   +1 more source

Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial. [PDF]

Sci Rep
Glal KAM, El-Haggar SM, Abdel-Salam SM, Mostafa TM.   +3 more
europepmc   +1 more source

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice ...
Geremia B. Bolli, Philip D. Home, Mauro Lepore, Matthew C. Riddle, Francesca Porcellati, Carmine G. Fanelli, Paola Lucidi, Hannele Yki‐Järvinen, Reinhard H. Becker, David R. Owens   +9 more
wiley   +1 more source

Prognostic Biomarkers for Predicting Decompensation in Alcoholic and Nonalcoholic Patients With Compensated Cirrhosis: An Umbrella Review. [PDF]

Biochem Res Int
Baktikulova K, Kurmangaliyeva S, Tamadon A, Kurmangaliyev K, Mussin NM, Safarzoda Sharoffidin R.   +5 more
europepmc   +1 more source

Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim We compared the impact of metabolic bariatric surgery (MBS) versus semaglutide on clinical outcomes in individuals with metabolic dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). Methods Patients with MASLD and T2D who had MBS or semaglutide in 2018–2023 were identified (TriNetX database).
Weronika Stupalkowska, Alex E. Henney, David R. Riley, Eric G. Sheu, Uazman Alam, Daniel J. Cuthbertson   +5 more
wiley   +1 more source

Radiomics-Based Assessment of Portal Hypertension Severity and Risk Stratification of Cirrhotic Patients Using Routine CT Scans. [PDF]

Liver Int
Sin C, Watzenboeck ML, Iofinova E, Balcar L, Semmler G, Scheiner B, Lampichler K, Mandorfer M, Moga L, Rautou PE, Ronot M, Menche J, Reiberger T, Scharitzer M.   +13 more
europepmc   +1 more source

Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Metabolic dysfunction–associated steatotic liver disease is common among individuals with type 2 diabetes mellitus and substantially increases the risk of liver cirrhosis and hepatocellular carcinoma. Effective therapies that improve metabolic control while preventing advanced liver outcomes are limited.
Assaf Issachar, Talish Razi, Ilya Borochov, Hadar Duskin Bitan, Ronen Arbel   +4 more
wiley   +1 more source

Antenatal and Neonatal Management of Siblings With Carbonic Anhydrase VA Deficiency. [PDF]

JIMD Rep
Manoy S, Minto T, Demetriou K, Lynch M, Selvanathan A, Jardine L, Lipke M, Bursle C, Inwood A, McGill J, Coman D.   +10 more
europepmc   +1 more source

Health Care Provider Perceptions of Screening for Early‐Stage Type 1 Diabetes—A Survey Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the feasibility, perceived benefits, and challenges of integrating early‐stage Type 1 diabetes screening and monitoring into routine care. Materials and Methods Primary health care providers (HCPs; n = 683), responsible for collecting capillary blood samples and obtaining informed consent, and specialised diabetes centres (n = 
Claire Cherdron, Peter Achenbach, Kathrin Ackermann, Florian Haupt, Anja Heublein, Annette Knopff, Sarah Schill, Jennifer Schmidt, Joanna Stock, Christiane Winkler, Anette‐G. Ziegler, Sandra Hummel   +11 more
wiley   +1 more source